Depo-Testosterone: Label, Generics, Prices and the Shortage

    Depo-Testosterone: Label, Generics, Prices and the Shortage

    November 18, 2026Editorial

    Depo-Testosterone is the brand name under which testosterone cypionate has been sold in the United States since 1951, first by Upjohn and today by Pfizer. Every generic testosterone cypionate vial in a US pharmacy is a copy of it, rated against it, and priced against it, and the brand itself has been listed on back order through 2025.

    This article covers what the brand is, what the current label says, which generics are rated equivalent to it, what the brand and the generics cost, the shortage, and the "Depo" confusion that pharmacists warn about. Sources: the Pfizer label revised October 2025, the FDA Orange Book listing, the FDA class-wide labeling notice of February 28, 2025, the ASHP shortage database, Health Canada's shortage report, GoodRx and Drugs.com price pages, and generic approval announcements.

    Key takeaway
    Maker
    Pfizer
    What it is
    Testosterone cypionate in cottonseed oil
    Strengths
    100 mg/mL (10 mL vials); 200 mg/mL (1 and 10 mL vials)
    Label dose
    50 to 400 mg every 2 to 4 weeks, deep IM
    Legal status
    Schedule III
    Warnings
    No boxed warning; blood pressure warning added in 2025
    Generics
    8 active makers plus Pfizer authorized generic, all rated AO
    Generic price
    About $13 to $19 per 1 mL vial with a discount card (2026)
    The brand has been listed on back order through 2025; generics are available intermittently.

    What the Name Means

    "Depo" stands for depot: a drug injected into tissue that releases slowly from where it sits. Upjohn used the prefix for several long-acting injections, which is why Depo-Testosterone shares it with Depo-Provera, a contraceptive progestin, and Depo-Medrol, a corticosteroid. The three are unrelated drugs.

    The product's history

    Year
    Event

    1951

    Testosterone cypionate introduced in the US as Depo-Testosterone by Upjohn

    Before 1982

    Current application (ANDA 085635) on record; the Orange Book gives no earlier date

    1995

    Upjohn merges with Pharmacia

    Early 2000s

    Pfizer acquires Pharmacia; the brand stays with Pfizer through the 2020 Upjohn–Mylan spin-off

    1978 to 2026

    Generic approvals, from Watson in the late 1970s through Cipla (2018), Eugia (2023) and BPI Labs (2026)

    February 2025

    FDA class-wide labeling change adds a blood pressure warning

    October 2025

    Current Pfizer label revision

    The 50 mg/mL strength once sold under the same application is discontinued.


    What the Label Says

    Depo-Testosterone label, October 2025

    Item
    Label text

    Indication

    Replacement therapy in males with primary hypogonadism or hypogonadotropic hypogonadism; safety in age-related low testosterone not established

    Dose

    50 to 400 mg every 2 to 4 weeks, deep intramuscular injection into the gluteal muscle, never intravenous

    Diagnosis

    Two morning testosterone levels below the normal range

    Strengths

    100 mg/mL (10 mL vial); 200 mg/mL (1 mL and 10 mL vials)

    Storage

    20 to 25 °C (68 to 77 °F), protected from light

    Schedule

    CIII controlled substance

    Each milliliter contains the hormone, cottonseed oil as the carrier, benzyl benzoate as a solubilizer and 9.45 mg of benzyl alcohol as a preservative:

    Inactive ingredients per mL

    Ingredient
    100 mg/mL
    200 mg/mL

    Benzyl benzoate

    0.1 mL

    0.3 mL

    Cottonseed oil

    736 mg

    470 mg

    Benzyl alcohol

    9.45 mg

    9.45 mg

    The 200 mg/mL strength carries three times the benzyl benzoate and less oil. The storage rules, and what happens to the oil in the cold, are on the refrigeration page; the volume arithmetic for each strength is on the 200 mg page.


    Warnings, and What Changed in 2025

    The label carries no boxed warning. Its warnings section covers:

    1. 1Blood pressure: "Testosterone can increase blood pressure which can increase cardiovascular (CV) risk over time"; not recommended in uncontrolled hypertension.
    2. 2Major adverse cardiovascular events, venous thromboembolism, and prostate enlargement and cancer in older men.
    3. 3Liver tumours and peliosis hepatis with long-term high doses, edema, gynecomastia and hypercalcemia in immobilized patients.
    4. 4Abuse, and use for athletic performance, which the label says is not an indication.
    5. 5Benzyl alcohol, which is toxic to newborns.

    On February 28, 2025 the FDA recommended class-wide changes for every testosterone product: the results of TRAVERSE, the cardiovascular outcomes trial, to be added; boxed language on cardiovascular risk removed from the products that carried it; and a blood pressure warning added to products that lacked one, after ambulatory monitoring studies "confirmed an increase in blood pressure with use of all testosterone products". For Depo-Testosterone the visible change is the blood pressure paragraph; its October 2025 label still describes the long-term cardiovascular data as inconclusive rather than citing TRAVERSE. In June 2026 HHS requested further changes, including removing the age-related limitation of use; those are requests, not yet label text. The numbers behind the blood pressure warning are on the blood pressure page.


    Generics: Are They the Same?

    The Orange Book lists Depo-Testosterone as the reference product and rates the active generics AO, the code for therapeutically equivalent injectable oil solutions. A pharmacist can substitute an AO-rated generic for the brand.

    Active generic testosterone cypionate makers (Orange Book, 2026)

    Maker
    Strengths

    Pfizer authorized generic (under its own ANDA)

    100 and 200 mg/mL

    Hikma (two applications)

    100 and 200 mg/mL

    Cipla (approved 2018)

    100 and 200 mg/mL

    Eugia, Aurobindo (approved 2023)

    100 and 200 mg/mL

    Xiromed

    100 and 200 mg/mL

    Padagis

    200 mg/mL

    Wilshire, American Regent, BPI Labs

    200 mg/mL

    Sun Pharma's generic, approved in 2013, and earlier Watson and Rising products are discontinued. Equivalence covers the hormone, strength, route and performance; a patient with a known sensitivity to an inactive ingredient, such as cottonseed oil or benzyl alcohol, should check the package insert of the specific maker.

    Azmiro, from Azurity, is a separate product: testosterone cypionate 200 mg/mL in single-dose vials and the first prefilled syringe, announced in December 2024. It has its own application and no equivalence code, so it cannot be swapped for Depo-Testosterone at the counter. Its single-dose pharmacokinetics are on the half-life page.


    Prices

    Cash prices, 2026

    Product
    Price
    Source

    Depo-Testosterone 200 mg/mL, 1 mL

    $12.39 to $28.80

    Drugs.com price guide

    Depo-Testosterone 200 mg/mL, 10 mL

    $142.86

    Drugs.com price guide

    Depo-Testosterone 100 mg/mL, 10 mL

    $44.70 to $93.29

    Drugs.com price guide

    Generic 200 mg/mL, 1 mL

    $18.98 lowest; about $43 average retail

    GoodRx, 2026

    Generic 200 mg/mL, 10 mL

    $42.60 lowest

    GoodRx, 2026

    One 1 mL vial, lowest with GoodRx Companion membership

    $13.08

    GoodRx, 2026

    $0$10$20$30$40$4.26Generic 10 mLlowest, GoodRx$12.39Brand 1 mLlowest, Drugs.com$14.29Brand 10 mLDrugs.com$18.98Generic 1 mLlowest, GoodRx$33.75Generic 1 mLaverage retailCash price per 200 mg of testosterone cypionate, 2026 listings

    The 10 mL generic vial is the cheapest way to buy the drug by a wide margin, about $4 per 200 mg against $12 to $34 for a single 1 mL vial. Insurance coverage, prior authorization and the full monthly cost including syringes and blood work are on the cost page.


    The Shortage

    Supply status by maker

    Maker
    Status
    Source and date

    Pfizer Depo-Testosterone, all presentations

    Back order

    ASHP, December 2024; still on back order July 2025

    Pfizer authorized generic

    Limited supply

    ASHP, December 2024

    Hikma 200 mg/mL 10 mL

    On allocation

    ASHP, July 2025

    Eugia

    Intermittent

    ASHP, July 2025

    Padagis, Cipla 1 mL

    Available

    ASHP, July 2025

    The shortage listing was opened in September 2019. Pfizer cites increased demand and manufacturing delays; Sun discontinued its product in late 2023 and Cipla its 10 mL vials in 2022. In Canada, Pfizer's 100 mg/mL product was short from January to October 2025. In practice a prescription written for "testosterone cypionate" rather than "Depo-Testosterone, dispense as written" is the one a pharmacy can fill.


    Recalls

    No recall of Pfizer's Depo-Testosterone was found. Several generic recalls are on record, all Class II or III: Cipla's 200 mg/mL 10 mL vials for particulate matter in March 2019; Sun Pharma's 200 mg/mL 1 mL vials for manufacturing deviations in June 2022; and, in April 2025, Eugia's 200 mg/mL 1 mL vials for "crystals not redissolving into solution after warming and shaking". A vial with visible particles, a damaged seal, or cloudiness or crystals that do not clear after warming and gentle shaking goes back to the pharmacy; crystals that do dissolve when warmed are the normal cold-storage effect covered on the refrigeration page.


    The "Depo" Mix-Up

    The Institute for Safe Medication Practices has reported dispensing errors among the Depo products, including a Depo-Provera and Depo-Medrol swap that led to a pregnancy, and recommends separate storage bins and tall-man lettering. No Depo-Testosterone-specific error case was found, but the safeguard for a patient is simple: the vial should read "testosterone cypionate" under the brand name, and the strength on the label should match the prescription. How to read the vial and draw the dose is on the injection guide.

    Frequently Asked Questions

    Pfizer's brand of testosterone cypionate injection, sold in the US since 1951: 100 mg/mL and 200 mg/mL in cottonseed oil, injected into muscle every 2 to 4 weeks for male hypogonadism. It is a Schedule III controlled substance.

    The active generics are rated AO in the FDA Orange Book, meaning therapeutically equivalent and substitutable. A patient sensitive to an inactive ingredient should check the specific maker's insert.

    Pfizer reports increased demand and manufacturing delays. The ASHP shortage listing shows the brand on back order since 2024, with several generics available or on allocation.

    Drugs.com lists a 1 mL 200 mg/mL vial at $12.39 to $28.80 and a 10 mL vial at about $143. Generic 10 mL vials start near $43 with a discount card.

    No. The current label has warnings on blood pressure, cardiovascular events, blood clots, the prostate and abuse, but no boxed warning. The 2025 class-wide update added the blood pressure warning.

    No. Depo-Provera is medroxyprogesterone, a contraceptive; Depo-Medrol is a corticosteroid. They share only the "Depo" prefix for depot injection.

    Cypionat.com is an independent educational resource. We are not affiliated with Pfizer, Azurity, Antares or any manufacturer, pharmacy or clinic. This content is for informational purposes only and does not constitute medical advice. Images on this site are illustrative artwork made for editorial purposes; they do not show real products, packaging or labels and are not an advertisement or an offer to sell.

    Editorial

    Author

    Share:TwitterFacebook

    Comments (0)

    Be the first to comment on this article.

    More articles

    Advertising